Date: 2016-01-19
Type of information: Production agreement
Compound: UCART123
Company: Cellectis (France) CellforCure (France)
Therapeutic area: Technology - Services
Type agreement: production manufacturing
Action mechanism: cell therapy/immunotherapy product/gene therapy. UCART123 targets CD123, an antigen expressed on the surface of cancer cells in malignancies, such as acute myeloid leukemia and blastic plasmacytoid dendritic cells neoplasm. UCARTs (Universal Chimeric Antigen Receptor T-cells) are “off-the-shelf” allogeneic product candidates.
Disease:
Details: * On January 19, 2016, Cellectis announced that it entered into a new agreement for the cGMP manufacturing of UCART123 clinical batches, with CellforCure, an LFB group company and the largest industrial facility for clinical and commercial production of innovative cell therapies in Europe. CellforCure will be in charge of implementing
cGMP manufacturing processes designed and developed by Cellectis. Following the recent successful production of UCART19, pursuant to this second agreement CellforCure will be responsible for the manufacturing of cGMP clinical batches for UCART123, the lead engineered T-cell product candidate in Cellectis’ wholly owned portfolio. UCARTs (Universal Chimeric Antigen Receptor T-cells) are “off-the-shelf” allogeneic product candidates. Their production can be industrialized and standardized with consistent pharmaceutical release criteria, over time and from batch to batch.
Peripheral Blood Monoculear Cells from healthy donors are transduced and genetically edited with Cellectis’ TALEN® technology to seek and destroy cancer cells. This approach could lead to a drug that would be cost-effective, made readily available - “off the shelf” - to broad patient populations in hospitals without need for local CAR-T processing facilities and easily distributed across all geographies.
Financial terms:
Latest news:
